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Abstract
Introduction: Legionnaires’ disease (LD), caused by the Legionella bacterium, is a rare but
serious atypical pneumonia that is often underdiagnosed in the clinical setting. Recent guideline
changes by the American Thoracic Society limited use of the urinary Legionella tests, the
primary form of diagnosis, due to the excessive costs of regular testing. Delays in testing and
diagnosis of LD result in increased cost of treatment and risk of death.
Objective: To develop a predictive model to estimate a patient’s probability of having LD. This
model would serve as a screen to better target diagnostic efforts, prevent misdiagnosis, and
reduce the overall cost of treatment for patients with LD.
Methods: Commonly collected hospital admission data including age, sex, admission month,
and clinical diagnosis were used to create backward elimination logistic regression models.
Additional non-hospital variables included smoothed incidence in home zip code and weather.
Models were trained on four data sets of community acquired pneumonia cases that differed by
location: New Jersey, New York (excluding NYC), New York City, and a combined data set of
all locations. A decision analysis was used to determine a cost-minimizing threshold.
Results: Using the models as a screen to guide diagnostic testing produced a wide range of
sensitivities despite consistently high specificities. The model trained on New York data
consistently performed the best on out of sample validation with the sensitivity of the screen
ranging between 0.96 and 0.99. Additionally, sensitivity analyses demonstrated that across a
range of prevalences, the models resulted in a lower cost per patient compared to testing all
patients. As the proportion of Legionella-attributable hospitalized pneumonia cases increased to
the expected proportion, the average savings per patient increased as well.

2

Conclusion: The models presented here can help guide clinicians in determining who should or
should not be tested for LD with the Legionella urine antigen test to reduce underdiagnosis,
decrease time to diagnosis, and improve health outcomes.
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Introduction
Legionella is a waterborne bacterium that can cause Legionnaires’ disease (LD), a serious and
sometimes fatal pneumonia; extrapulmonary legionellosis; and Pontiac fever, a self-limited flulike illness.1 Across the United States, there has been a 129% increase in the incidence of
legionellosis from 2012-2018.2,3 Despite this increase, research suggests that legionellosis is
substantially underdiagnosed with only 10.6% of true cases identified.4,5
Although underdiagnosed, Legionella’s share of serious hospital cases of pneumonia is
disproportionately large. While only 1-5 percent of adult pneumonia cases are attributable to
Legionella, it is often overlooked as a causative agent.6 Additionally, LD is difficult to diagnose
without molecular testing because clinical presentation is similar to atypical pneumonias.1
However, as clinical disease severity progresses, so does the proportion of cases attributable to
Legionella, with the bacterium being the second leading cause of pneumonia requiring treatment
in the intensive care unit (ICU).7 The mortality rate ranges from 5-30% with treatment; factors
such as the concentration of Legionella exposure, comorbidities, and delay in diagnosis and
appropriate treatment can result in a greater likelihood of death.8 Without proper treatment, the
mortality rate can increase to 40-80% in immunocompromised populations.8
Misdiagnosis of type of pneumonia has consistently been shown to be associated with longer
hospital stays and increased costs of treatment.9,10 While community acquired pneumonia (CAP)
is typically treated empirically, approximately 15 percent of CAP cases result in treatment
failure; the main drivers of cost were additional days spent in the hospital and the need for
intensive care treatment.9 On average, patients spent approximately 3 extra days at the hospital
and had a significantly higher rate of admission compared to those who were appropriately
diagnosed and treated.11 The preferred antibiotic class used to treat LD are fluoroquinolones,
however azithromycin and doxycycline can also be used.12 Additionally, because the antibiotics
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must penetrate into alveolar macrophages to reach the bacteria, antibiotic dosage is also
important.12 While the actual effects of underdiagnosis of LD have not been well documented,
failure of the Legionella bacteria to respond to commonly used first-line antibiotics make
diagnosis important.
Current guidelines from the American Thoracic Society do not recommend that healthcare
providers should test urine for Legionella antigen except in the case of severe pneumonia or if
there is epidemiological evidence for LD including recent travel or an active Legionella
outbreak, mainly due to the high cost of previous guidelines which indicated all hospitalized
pneumonia patients should be tested.13 As a result, usage of the Legionella Urine Antigen test are
inconsistent and subject to the judgement of the health care provider. In order to decrease the
number of undiagnosed cases and reduce the time to diagnosis, more must be done to support the
clinician in this decision-making process. To this end, we created an easily implementable
predictive model for Legionnaires’ disease to serve as a screening tool for screening to help
decide when urine antigen testing might be appropriate for hospitalized cases of communityacquired pneumonia.
This model differs from previous attempts to create a diagnostic model for LD by using variables
present on admission as well as variables not previously been considered for a model of this type
such as weather and incidence rate in patients home zip code. Previous attempts to create a
predictive diagnostic model have relied on clinical aspects such as absence of cough, lactate
dehydrogenase (LDH), and sodium levels.14 Many of these attempts have failed because
pneumonia presents in a similar fashion regardless of the causative pathogen.
In this study, we describe a predictive model using diagnostic codes present on admission,
weather, and IR in home zip codes to calculate the probability that a patient hospitalized for
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pneumonia has LD. Using a decision analysis framework, we calculate the optimal threshold
cutoff over which cases will be tested to minimize the average cost per patient in order to reduce
excessive testing and associated costs. As with any screening tool, there are health risks and
economic costs associated with both over- and under-referral for diagnostic testing; overly
aggressive referral results in avoidable costs, on the other hand insufficient referrals would lead
to costly and potentially harmful delays in appropriate care.
Methods:
Data for predictive model:
Hospitalized cases of pneumonia in the states of New Jersey and New York from 2004-2014
were obtained from the Healthcare Cost and Utilization Project (HCUP) database. Variables
included grouped diagnostic and procedural ICD-10 codes (DXCCS, PRCCS), age, zip code,
Legionella diagnosis status, and admission month.
To ensure only community-acquired cases were considered, the data was subset to include cases
with a diagnosis of pneumonia on admission. Additionally, only diagnostic codes that were
present on admission at least 80 percent of the time were considered to prioritize diagnostic
codes that were most often available at admission.
Variables included in the predictive model were chosen because they have previously and
consistently been shown to be risk factors for LD. Weather has repeatedly been a demonstrated
risk factor for LD, specifically temperature, humidity and rainfall.15 Spatial variability,
potentially due to factors such as differences in the environment, relationship to known outbreak
sources, and indicators of socioeconomic status exists in LD incidence rate and has been shown
at the zip code level; thus, zip code incidence rates were used.16
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Legionella cases from years 2008-2011, half of the available data, were used to determine a
baseline incidence rate map by zip code for New Jersey, New York, and New York City. To
account for spatial autocorrelation of baseline disease incidence by zip code, a smoothed
estimate of incidence was created using a Bayesian conditional autoregressive model. This
model assumes that zip codes sharing a border are more similar in baseline LD incidence than
zip codes that are not spatially connected (Figure 1).17

Figure 1: Incidence Rate Maps. The top row shows the observed incidence rates (IR)
by zip code for each of the three locations. The bottom map shows the smoothed
version, so that each zip code accounts for IR values in neighboring zip codes as well.

Weather data were obtained from the National Oceanic and Atmospheric Administration
(NOAA) through the Local Climatological Data tool. Harmonic regression was performed on the
temperature to remove the seasonal trends. Temperature was deseasonalized to use the effect of
deviations from the mean within the model. Previous studies have indicated that aberrations in
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temperature, precipitation and humidity are associated with increases in LD approximately two
weeks later.15 Precipitation did not show seasonal trends and was not deseasonalized. Relative
humidity data for New Jersey was downloaded from Climate Data Online (CDO) at an hourly
level. Hourly humidity measurements were averaged to the monthly level. Like precipitation,
humidity data did not show seasonal trends to the same extent as did temperature and was not
deseasonalized.
For New Jersey, data was downloaded as the monthly average which was then averaged across
all six different locations in New Jersey: Atlantic City International Airport, McGuire Airforce
Base, Morristown, Newark Liberty International Airport, Ocean County Airport, and Cape May
Airport. Station locations were chosen based on distribution throughout the state.
The same methodology was followed for New York data. Weather stations used were La
Guardia International Airport for New York City and New York state, as well as Albany
International Airport, Buffalo Niagara International Airport, and Syracuse Hancock International
Airport for New York State (Figure 2). Humidity data was available from this source for New
York.
Logistic Regression Models:
In order to identify clinical diagnoses most commonly associated with an LD outcome to use in
model creation, a market basket analysis, a data-mining technique used to identify associations
between variables and outcomes, was performed.18 The eight most common diagnoses were
identified from the market basket analysis for use in logistic regression models. These included:
septicemia; fluid/electrolyte disorder; renal failure; history/screening of mental health/substance
abuse; connective tissue disorders; respiratory failure; alcohol related disorder; and other liver
disease (Appendix-1).
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Figure 2: Weather Data. Precipitation, relative humidity, and temperature were obtained at a
monthly level for all three locations. Temperature data was deseasonalized to avoid
conflicting with admission month which accounted for seasonal patterns within the data. The
data above were used as the weather measurements in the logistic regression models.
Logistic regression was used to create a model predicting probability of LD. Logistic regression
was run on 70% of available data, while the remaining 30% was used as a validation data set.
Variables included diagnostic codes identified in the market basket analysis, age, sex,
temperature variables, and smoothed incidence rate in home zip code. Backward elimination was
used to remove variables that were not significant in predicting risk of disease. Model output is
the probability that a given hospitalized pneumonia case would be diagnosed with LD.
Models were evaluated by creating receiver operating characteristic (ROC) curves, plotting
sensitivity vs 1-specificity of the screen. The area under the curve (AUC) was calculated. A
larger resulting AUC score was considered to be a better model. Models stratified by age or sex
were created but had lower AUC values than non-stratified models and were not considered.
12

Models were used to predict disease in the remaining 30% that was withheld as a validation data
set as well as in the additional two regions.
Optimal Threshold Calculations and Applications:
The model output is a calculated probability that an observation has LD given the variables
associated with that observation; a decision analysis was used to evaluate the optimal cutoff
probability for which a patient should undergo a diagnostic test for LD. A decision analysis was
used to calculate an evidence-based balance between over and under referral for diagnostic
testing. This optimal cut off threshold mathematically determined the point at which the cost per
patient was minimized.19
Parameters used to estimate cost were identified. Costs were estimated using a modified equation
from a report on the cost-effectiveness of microbiological tests for moderate and severe CAP
patients commissioned by the National Institute for Health and Care Excellence (NICE) in the
UK. Some costs were derived from the HCUP data base including cost of a day in a regular
hospital room or an ICU room. Additionally, estimates taken from the NICE report such as
average length of stay in the ICU and the average length of stay in the hospital were confirmed
using HCUP data. Final estimates are shown in (Appendix-2).
The cost-minimizing threshold cutoff was calculated as a function of the relative magnitude of
the cost of over or under testing, the prevalence of disease, and how well the screen/diagnostic
strategy differentiates between cases and noncases. If too many people are referred for diagnostic
testing, the strategy runs the risk of overscreening which can be expensive. However, if too few
people are referred to diagnostic testing the number of false negatives will increase, and patients
will not receive appropriate care (Appendix-3).
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After obtaining the cost-minimizing threshold, this threshold was applied to each of the models
to calculate the sensitivity and specificity a model would have on a given dataset. Sensitivity of
the combined screen and diagnostic test was calculated by multiplying the two sensitivities.
Specificity was calculated by specscreen + (1- specscreen)*spectest. Sensitivity analysis was
performed to understand how cost per patient changed as the threshold was increased or
decreased as well as how the optimal threshold changed as base prevalence of Legionella cases
in hospitalized pneumonia cases changed.
Results:
Descriptive Statistics:
Between datasets from New Jersey, New York, and New York City, there were 2,397,204
respiratory infection hospitalizations. Of those, 1,291,317 had a diagnosis of pneumonia present
on admission and were considered to be cases of community-acquired pneumonia. There were
4184 total cases of Legionnaires’ Disease among those CAP cases; cases of Pontiac fever and
extrapulmonary legionellosis were not considered. This represents a prevalence of 0.32% of LD
among hospitalized cases of CAP across all years. Of diagnosed cases of LD, 62 percent were
male, and the mean age was 63 (Table 1).
Table 1. Descriptive Statistics
Characteristic, n (%)
Total CAP
Legionellosis Pos
Gender*
Male
Female
Age category*
Under 40
40-59
60-79
80+

New Jersey
(n=391,888)
1187 (0.30)

New York
(n=576,278)
2551 (0.44)

New York City
(n=323,151)
1292 (0.40)

Combined
(n = 1,291,317)
4184 (0.32)

769 (64.7)
418 (35.2)

1585 (62.1)
966 (37.9)

774 (59.9)
518 (40.0)

2594 (62.0)
1590 (38.0)

77 (6.5)
420 (35.4)
519 (43.7)
171 (14.4)

173 (6.8)
914 (35.8)
1043 (40.9)
421 (16.5)

85 (6.6)
410 (31.7)
541 (41.9)
256 (19.8)

254 (6.1)
1388 (33.2)
1816 (43.4)
726 (17.4)

*of Legionella positive cases
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Logistic Regression:
Four logistic regression models were created, all of which started with the same variables
identified from the market basket analysis. The models differed in their underlying data:
1) New Jersey 2008-2013;
2) New York (excluding New York City) 2007-2013;
3) New York City 2007-2013;
4) data from New York, New York City and New Jersey.
Across the four models, the majority of variables substantially improved the fit of the model.
Alcohol related disorder, residual temperature, and humidity were the only variables excluded
across all models; respiratory failure was used in the New Jersey and the combined model, while
year was excluded from the New Jersey model, but significant in the other three models (Table
2).
Table 2. Model Parameter Estimates
Model Variable
Estimate (p-value)
Septicemia
Fluid/Electrolyte Disorder

Renal Failure
Hx of MH/SB+
Connective Tissue Disorder

Respiratory Failure
Alcohol Related Disorder

Other Liver Disease
Female
40-59
60-79
80+
Residual Temp
Humidity
Pred IR
Precipitation
February
March
April
May
June
July
August
September
October
November
December
2008

New Jersey
(n=274,321)
0.37 (***)
0.73 (***)
0.72 (***)
0.59 (**)
1.00 (***)
ns
ns
0.37 (**)
-0.54 (***)
0.91 (***)
0.49 (***)
-0.30 (ns)
ns
ns
0.04 (***)
0.06 (***)
-0.13 (ns)
-0.05 (ns)
-0.34 (ns)
0.49 (*)
1.12 (***)
1.06 (***)
1.33 (***)
1.28 (***)
1.12 (***)
0.57 (***)
0.20 (ns)
ns

New York
(n=403,394)
0.78 (***)
0.69 (***)
0.72 (***)
0.59 (***)
0.89 (***)
ns
ns
ns
-0.39 (***)
0.84 (***)
0.30 (**)
-0.31 (*)
ns
ns
0.02 (***)
0.02 (***)
-0.24 (ns)
-0.07 (ns)
-0.07 (ns)
0.27 (ns)
1.17 (***)
1.29 (***)
1.71 (***)
1.26 (***)
0.74 (***)
0.51 (***)
-0.02 (ns)
0.20 (ns)

New York City
(n=226,205)
0.38 (***)
0.57 (***)
0.89 (***)
0.28 (*)
1.07 (***)
ns
ns
0.35 (**)
-0.34 (**)
1.24 (***)
0.76 (***)
0.19 (ns)
ns
ns
0.06 (***)
0.06 (***)
0.49 (ns)
0.14 (ns)
-0.21 (ns)
0.78 (**)
1.74 (***)
1.73 (***)
1.76 (***)
1.89 (***)
1.29 (***)
1.13 (***)
0.36 (ns)
-0.37 (*)

Combined
(n = 903,921)
0.54 (***)
0.66 (***)
0.82 (***)
0.50 (***)
0.92 (***)
-0.18 (***)
ns
0.41 (***)
-0.42 (***)
1.01 (***)
0.52 (***)
-0.14 (ns)
ns
ns
0.03 (***)
0.01 (**)
-0.15 (ns)
-0.15 (ns)
-0.13 (ns)
0.38 (***)
1.23 (***)
1.24 (***)
1.57 (***)
1.35 (***)
0.97 (***)
0.54 (***)
0.22 (ns)
0.16 (ns)
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2009
ns
0.23 (*)
0.03 (ns)
0.25 (**)
2010
ns
0.03 (ns)
-0.11 (ns)
0.02 (ns)
2011
ns
-0.05 (ns)
-0.19 (ns)
0.22 (*)
2012
ns
0.04 (ns)
-0.35 (*)
0.05 (ns)
2013
ns
0.29 (**)
0.22 (ns)
0.42 (***)
2014
ns
0.16 (ns)
0.07 (ns)
0.14 (ns)
ns: not significant; ***: p – value < 0.001 ; **: p-value < 0.01; *: p-value < 0.05; n: number of observations
model trained on. + - history/screening of mental health/substance abuse

Model Validation:
In order to understand the model’s performance, an ROC curve of sensitivity versus 1-specificity
of the predicted outcome was graphed to display the balance between sensitivity and specificity
of the model (Appendix-4). Area under the curve (AUC) was calculated for each ROC curve
(Table 3). All models had consistent AUC values across all data sets. Additionally, AUC values
were similar between all of the models; all AUC values ranged between 0.7815 and 0.8123. The
New York model had the lowest values on validation data sets with AUC values of 0.7841 on the
validation dataset and 0.7842 on both New Jersey and New York City. The New Jersey model
had the most consistent AUC values, with all four values between 0.7912 and 0.8002. It is
possible that discrepancies between AUC values are the result of noise within the models.
Table 3. Area Under the Curve Values
New Jersey
AUC:
Train Set
Valid Set
New Jersey
New York
New York City
*Area Under the Curve

0.7912
0.7917
--0.8002
0.7944

New York

New York City

Combined

0.8123
0.7841
0.7842
--0.7842

0.8105
0.7922
0.805
0.8106
---

0.7815
0.7957
-------

Optimal Threshold Calculation and Application:
The optimal threshold cutoff was calculated taking into account factors such as the prevalence of
disease in the sample, the cost ratio, and the tests ability to differentiate between cases and
noncases. The low incidence of LD resulted in a very low probability threshold for the model to
recommend diagnostic testing. The optimal threshold was relatively consistent for each model
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ranging from 0.003-0.01. Using the calculated threshold, sensitivity and specificity of the models
were calculated for each dataset (Table 4). For example, when a threshold of >0.003 was applied
to the New Jersey model, all patients who had a calculated probability of LD of greater than
0.003 were referred to additional diagnostic screening. Because of the sensitivity of the
diagnostic test, the sensitivity of the combined strategy could not exceed 0.7. Sensitivity of the
diagnostic test is estimated at 0.99.20
Table 4. Model Sensitivity and Specificity
New Jersey
Threshold:

Train Set
Valid Set
New Jersey
New York
New York City

(>0.003)

0.489
0.997
0.493
0.997
--0.611
0.995
0.543
0.997

New York

New York City

Combined

(>0.01)

(>0.009)

0.435
0.998
0.694
0.991
0.674
0.992

0.264
0.999
0.252
0.999
0.261
0.999
0.431
0.998

0.269
0.999
0.274
0.999
---

(>0.005)

--0.676
0.992

---

-----

Top number represents sensitivity; bottom number in each cell is specificity.
Combined with the sensitivity and specificity of the diagnostic test, this resulted in a sensitivity
of 0.611 and 0.543 as well as a specificity of 0.995 and 0.997 in New York and New York City,
respectively. Overall, the New Jersey and New York models had higher sensitivities on datasets
outside of the training set compared to the New York City and combined model. In fact, the New
York model had the highest sensitivities, only slightly below the maximum sensitivity set by the
diagnostic test. These high sensitivities indicate that using a model like this would serve as a
good screen for targeting diagnostic testing allowing clinicians to capture almost as many
patients with LD compared to using the urine antigen test on all patients. The specificities of the
models were all high, ranging from 0.992 to 0.999.
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To better understand the impact of applying such a model, we examined the average cost per
patient, the number of patients that would receive a diagnostic test, as well as the number of true
positives, false positives, false negatives, true negatives, and total number of misdiagnosed cases
for each strategy test all, screen and test, and test none, if the New York model was applied in
New Jersey, New York and New York City (Table 5). Compared to testing all, the screen and
test strategy saves approximately $16-30 per patient and reduces the number of tests by 10-20
percent, while also reducing the number of misdiagnosed patients.
Table 5. New York Model Applied to New Jersey, New York, New York City

New Jersey
Test All
Screen/Test
Test None
New York
Test All
Screen/Test
Test None
New York City
Test All
Screen/Test
Test None

Avg. Cost
per
Patient

Patients
Tested

41,891.30
41,860.30
41,763.08

391888
313703
0

41,903.18
41,887.50
41,790.3
41,889.53
41,868.84
41,781.98

True
Positives

False
Positives

False
Negatives

True
Negatives

Cases
Misdiagnosed

830.9
800.0
0

3907.0
3125.6
0

356.1
386.9
1187

386793.9
387575.4
390701

4263.1
3925.6
1187

576,278
518,883
0

1785.7
1770.4
0

5737.3
5163.5
0

765.3
780.6
2551

567,989.7
568,563.5
573727

6502.6
5944.1
2551

323,151
258,735
0

904.4
873.4
0

3218.6
2574.9
0

387.6
418.6
1292

318,640.4
319,284.1
321,859

3,606.2
2,993.5
1292

Sensitivity Analyses:
Using these calculated thresholds, the average cost per patient was calculated and compared to
the average cost per patient of performing the diagnostic test on all patients and on no patients.
As the threshold increased, the average cost per patient approached the cost of using the
diagnostic test on no one, as the screen would indicate fewer and fewer people for testing. The
graphed curve of average cost per patient by threshold is remarkably flat, indicating that shifting
the optimal threshold in either direction would make little difference on the average cost per
patient. Compared to the average cost per patient of using the diagnostic test on all patients,
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using the screen resulted in a lower cost per patient at all threshold levels (Figure 3). The
discontinuity observed in the graph of New York is likely due to noise within the model.

Figure 3: Estimated Cost Per Patient by Threshold Cutoff. Each graph shows the average cost per
patient for each of the three strategies: 1) using the screen and diagnostic test (solid line); 2) testing all
hospitalized pneumonia patients with the diagnostic test (dashed line); 3) testing no patients with the
diagnostic test (dashed and dotted line). The vertical red line indicates the optimal threshold cutoff.
The relative flatness of the curves around the optimal threshold indicates that shifting the cutoff in
either direction would not dramatically alter costs.

Because the true proportion of hospitalized pneumonia cases attributable to Legionnaire’s
disease is thought to be severely underestimated, the effect of changes in prevalence of cases
within hospitalized pneumonia patients on threshold cutoff was determined. For two of the
models, the combined and NYC models, at no point were the models effective for a prevalence
of 0.0001. However, as the prevalence increased, the threshold cutoff decreased, increasing the
number of people the screen would indicate for testing. Between 2-5% prevalence, the
recommended threshold cutoff would vary between 0.0005 and 0.002 (Figure 4). Lower
thresholds would result in higher sensitivities without significantly reducing the specificity.
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Figure 4: Threshold Cutoff
by Prevalence. This graph
shows the change in threshold
cutoff as the underlying
prevalence, or proportion of
hospitalized pneumonia cases
due to LD, changes. In many
of these data sets, the
observed prevalence is around
0.003, on the left-hand side of
the graph; however, expected
values of the prevalence range
from 2-5% where there is less
variability in the expected
threshold cutoff.

Figure 5: Avg Cost per Patient by Prevalence.
The three strategies are modeled here: 1)
diagnostic testing all patients (green); 2)
diagnostic testing on no patients (blue); and screen
and testing (black). The three separate black lines
indicate the model applied to each of the three
location datasets, demonstrating that the models
perform similarly irrespective of the location it is
being applied to.

Finally, we were able to calculate the expected average cost per patient using all three strategies:
screen and test as indicated, test all, and test none, as the prevalence of disease within
hospitalized pneumonia cases changed. As prevalence increases, the cost per patient of testing no
20

one increases dramatically (Figure 5). For all four models, the cost of testing all is higher than
the cost of the screen/test method across the majority of prevalences tested, however, as the
prevalence increases the difference between these two estimated costs narrows. Over the
expected true proportion of cases of hospitalized pneumonia due to LD, using the predictive
model as a screen to indicate who should be tested costs less per person than does testing all
cases and testing no cases.
Conclusions
Summary & Key Findings:
Here, we describe a predictive model to serve as a screen for patients hospitalized with
community acquired pneumonia has LD to indicate for diagnostic testing. Unlike past diagnostic
models for LD that use clinical biomarkers to attempt to differentiate between cases and
noncases, this model focuses on information already being collected in clinical settings and could
ideally pull this information automatically from patient records to provide a recommendation for
clinicians about further diagnostic testing.
Across all four models, the average cost per patient based on the screen/diagnostic test method
cost less than did testing all hospitalized pneumonia patients and testing no patients for LD. The
cost at varying threshold cutoffs were relatively similar and clinicians could err on the side of
lower threshold cutoffs to increase sensitivity without significantly affecting the cost per patient.
While the difference in costs at the observed prevalence was low, as the prevalence increased
into what the expected prevalence truly is the savings grew, indicating that a better
understanding of the true proportion of pneumonia hospitalizations that are due to LD is
important. Additionally, increasing trends of LD in the United States and how this increase will
infect prevalence of LD among hospitalized pneumonia cases will be important to consider for
implementing this model.
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Public Health Relevance:
Recently revised guidelines from the American Thoracic Society indicate that a Legionella Urine
Antigen Test should be used only for diagnostic purposes in severe cases of pneumonia in order
to reduce the number of tests being performed. A screening tool like the one described here can
help delineate more objectively who should or should not be tested to improve LD diagnosis
rates. More effective diagnosis will result in more targeted treatment preventing unnecessary
antibiotics, improvement in clinical outcomes, and a reduction in the cost of misdiagnosis in
hospitalized pneumonia cases.
Strengths and Limitations:
New York City was separated from New York due to the possibility of different LD dynamics. It
is thought that specific attributes of NYC including population and cooling tower density play a
central role in LD epidemiology in New York City that might not be applicable in the rest of the
state. However, the similarities between the models as well as the high performance of New
York and New Jersey models on New York City data indicate that this model could be useful
across different LD populations and settings. Additionally, the observed proportion of
hospitalized pneumonia cases is much lower than expected, suggesting that as this surveillance
improves the screen has the potential for larger cost savings.
Limitations of this approach reflect lack of detailed data. Efforts to improve this method could
consider implementing patient travel history. Forty percent of LD are travel-related, making it an
important factor to account for when predicting risk of disease.21 In addition to travel-related
cases, little is known about whether more cases are infected near their home or while they are out
and about going to work, running errands, etc. The models above indicate that smoothed IR by
zip code is significant in predicting risk of disease, however, that does not rule out the possibility
that risk might be greater away from the home. Additionally, information about chronic diseases
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could be important for predicting risk of disease; the dataset did not clearly indicate whether a
condition was chronic or a result of the current respiratory hospitalization so it was unable to be
used to better understand what chronic conditions might be most related to a diagnosis of
Legionellosis.
Finally, it is important to recognize the potential for inaccuracies among the dataset. Because
Legionellosis is thought to be underdiagnosed, all of the data the models were trained on likely
reflected this underdiagnosis, which could introduce bias into the model. More accurate
diagnosing and understanding of risk factors for Legionellosis could improve model performance
for better health and economic outcomes moving forward.
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Appendix:
1. DXCCS Codes included within the model:
The Healthcare Cost and Utilization Project (HCUP) uses the Clinical Classification Software
(CCS) to classify ICD-9 codes into larger subgroups of diagnostic codes (DXCCS). For example,
a diagnosis of pneumonia (except that caused by tuberculosis or sexually transmitted disease), or
DXCCS 122, is comprised of all of the following ICD-9 codes: 00322, 0203, 0204, 0205, 0212,
0221, 0310, 0391, 0521, 0551, 0730, 0830, 1124, 1140, 1144, 1145, 11505, 11515, 11595, 1304,
1363, 4800, 4801, 4802, 4803, 4808, 4809, 481, 4820, 4821, 4822, 4823, 48230, 48231, 48232,
48239, 4824, 48240, 48241, 48242, 48249, 4828, 48281, 48282, 48283, 48284, 48289, 4829,
483, 4830, 4831, 4838, 4841, 4843, 4845, 4846, 4847, 4848, 485, 486, 5130, and 5171. There are
approximately 300 DXCCS codes.22
A market basket analysis was performed to identify the top eight most common DXCCS codes
associated with a concurrent diagnosis of LD. Those DXCCS codes are as follows:
DXCCS Code
DXCCS 2

Grouped Diagnosis
Septicemia (except in
labor)

DXCCS 55

Fluid and Electrolyte
Disorders
Acute and unspecified
renal failure
Screening and history
of mental health and
substance abuse codes

DXCCS 157
DXCCS 663

Corresponding ICD-9 Codes
0031, 0202, 0223, 0362, 0380, 0381, 03810, 03811, 03812, 03819,
0382, 0383, 03840, 03841, 03842, 03843, 03844, 03849, 0388,
0389, 0545, 449, 77181, 7907, 99591, 99592
2760, 2761, 2762, 2763, 2764, 2765, 27650, 27651, 27652, 2766,
27669, 2767, 2768, 2769, 9951
5845, 5846, 5847, 5848, 5849, 586
3051, 30510, 30511, 30512, 30513, 33392, 7903, V110, V111,
V112, V113, V114, V118, V119, V154, V1541, V1542, V1549,
V1582, V6285, V663, V701, V702, V7101, V7102, V7109, V790,
V791, V792, V793, V798, V799

DXCCS 211

Other connective tissue
disease

32752, 56731, 7105, 725, 7260, 72610, 72611, 72612, 72613, 72619, 7262, 72630,
72631, 72632, 72633, 72639, 7264, 7265, 72660, 72661, 72662, 72663, 72664,
72665, 72669, 72670, 72671, 72672, 72673, 72679, 7268, 72690, 72691, 72700,
72701, 72702, 72703, 72704, 72705, 72706, 72709, 7272, 7273, 72740, 72741,
72742, 72743, 72749, 72750, 72751, 72759, 72760, 72761, 72762, 72763, 72764,
72765, 72766, 72767, 72768, 72769, 72781, 72782, 72783, 72789, 7279, 7280,
72810, 72811, 72812, 72813, 72819, 7282, 7283, 7284, 7285, 7286, 72871, 72879,
72881, 72882, 72883, 72884, 72885, 72886, 72887, 72888, 72889, 7289, 7290, 7291,
7292, 72930, 72931, 72939, 7294, 7295, 7296, 72971, 72972,72973, 72979, 72981,
72982, 72989, 7299, 72990, 72991, 72992, 72999, 7819, 78191, 78192, 78194,
78199, 7937, V135, V1359, V436, V4360, V4361, V4362, V4363, V4364, V4365,
V4366, V4369, V437, V454, V481, V482, V483, V490, V491, V492, V495, V4960,
V4961, V4962, V4963, V4964, V4965, V4966, V4967, V4970, V4971, V4972,
V4973, V4974, V4975, V4976, V4977, V537

DXCCS 131

Respiratory failure;
insufficiency; arrest
(adult)
Alcohol-related
disorders

5173, 5185, 51851, 51852, 51853, 51881, 51882, 51883, 51884,
7991, V461, V4611, V4612, V4613, V4614, V462

DXCCS 660

DXCCS 151

Other liver diseases

2910, 2911, 2912, 2913, 2914, 2915, 2918, 29181, 29182, 29189,
2919, 30300, 30301, 30302, 30303, 30390, 30391, 30392, 30393,
30500, 30501, 30502, 30503, 3575, 4255, 5353, 53530, 53531,
5710, 5711, 5712, 5713, 76071, 9800
570, 5715, 5716, 5718, 5719, 5720, 5721, 5722, 5723, 5724, 5728,
5730, 5734, 5735, 5738, 5739, 7824, 7891, 7895, 78959, 7904,
7905, 7948, V427
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2. Cost Calculations:
Input
Variable
Name
CUAT

Input Variable
Definition

Estimated
Value

Source

Cost of Urine
Antigen Test

$29

CDRT

Cost of Diagnostic
Radiology Tests
Cost of Diagnostic
Molecular Testing
Cost of 1 day of
inpatient hospital
treatment
Cost of 1 day in
the ICU
Average length of
stay for patients
diagnosed with LD

$1700

Chen, D. J., Procop, G. W., Vogel, S., YenLieberman, B., & Richter, S. S. (2015).
Utility of PCR, Culture, and Antigen
Detection Methods for Diagnosis of
Legionellosis.
https://doi.org/10.1128/JCM.01808-15
Averaged from HCUP database

$1500

Averaged from HCUP database

$4255

Averaged from HCUP database

$6441

Averaged from HCUP database

10 days

Henry, C., Boethel, C., Copeland, L. A.,
Ghamande, S., Arroliga, A. C., & White, H. D.
(2017). Clinical utility of testing for legionella
pneumonia in central Texas. Annals of the
American Thoracic Society, 14(1), 65–69.
https://doi.org/10.1513/AnnalsATS.201606501BC

CDMT
CHT
CICU
LOS_LD

LOS_OP

ALOS_ICD

Average length of
stay for patients
diagnosed with
other pneumonias

7 days

Average additional 3 days
length of stay due
to an initial
incorrect diagnosis

Confirmed by averaging LOS of Legionella
patients in HCUP database.
National Clinical Guideline Centre. Clinical
Guideline 191: Cost-Effectiveness Analysis for
Microbiological Tests in Patients with
Moderate-and High-Severity CommunityAcquired Pneumonia.; 2014.
Confirmed by averaging LOS of Legionella
patients in HCUP database.
National Clinical Guideline Centre. Clinical
Guideline 191: Cost-Effectiveness Analysis for
Microbiological Tests in Patients with
Moderate-and High-Severity CommunityAcquired Pneumonia.; 2014.
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LOS_ICU

Average length of
stay in ICU

3 days

LOS_Death

Average length of
additional days
stayed if the
patient passes
away

7 days

Probabilities of Transfer to ICU
P(ICU|CLD
Probability that a
D)
patient needs the
ICU given a
correct diagnosis
of LD
P(ICU|CPD) Probability that a
patient needs the
ICU given a
correct non LD
diagnosis
AP(ICU|ICD Additional added
)
probability of ICU
stay for incorrect
diagnosis
Probabilities of Death
P(D|CLDD) Probability of
death given a
correct diagnosis
of LD
P(D|ICLDD)

Probability of
death given an
incorrect diagnosis
of LD

Micek, S. T., Lang, A., Fuller, B. M., Hampton,
N. B., & Kollef, M. H. (2014). Clinical
implications for patients treated inappropriately
for community-acquired pneumonia in the
emergency department. BMC Infectious
Diseases, 14(1), 61.
https://doi.org/10.1186/1471-2334-14-61
National Clinical Guideline Centre. Clinical
Guideline 191: Cost-Effectiveness Analysis for
Microbiological Tests in Patients with
Moderate-and High-Severity CommunityAcquired Pneumonia.; 2014.
National Clinical Guideline Centre. Clinical
Guideline 191: Cost-Effectiveness Analysis for
Microbiological Tests in Patients with
Moderate-and High-Severity CommunityAcquired Pneumonia.; 2014.

0.4

Alarcon Falconi TM, Cruz MS, Naumova EN.
The Shift in Seasonality of Legionellosis in the
U.S. Epidemiol Infect. 2018;146(14):1824-1833.
doi:10.1017/S0950268818002182

0.12

Storms AD, Chen J, Jackson LA, et al. Rates and
risk factors associated with hospitalization for
pneumonia with ICU admission among adults.
BMC Pulm Med. 2017;17(208).
doi:10.1186/s12890-017-0552-x
No estimates were available for increased risk of
ICU need with a misdiagnosed pneumonia;
however if mortality increases, it can be assumed
there is also an increased risk of ICU.

0.05

0.11

0.15

Centre, N. C. G. (2014). Pneumonia (communityand hospital-acquired): Cost-effectiveness
analysis for microbiological tests in patients with
moderate-and high-severity community-acquired
pneumonia.
Centre, N. C. G. (2014). Pneumonia (communityand hospital-acquired): Cost-effectiveness
analysis for microbiological tests in patients with
moderate-and high-severity community-acquired
pneumonia.
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P(D|CPD)

Probability of
death given a
correct pneumonia
diagnosis

0.128

P(D|ICPD)

Probability of
death given an
incorrect
pneumonia
diagnosis

0.14

Weighted probability from other species of
pneumonia pathogens calculated from:
Centre, N. C. G. (2014). Pneumonia (communityand hospital-acquired): Cost-effectiveness
analysis for microbiological tests in patients with
moderate-and high-severity community-acquired
pneumonia.
Weighted probability from other species of
pneumonia pathogens calculated from:
Centre, N. C. G. (2014). Pneumonia (communityand hospital-acquired): Cost-effectiveness
analysis for microbiological tests in patients with
moderate-and high-severity community-acquired
pneumonia.

Cost True Positive = (Cost of Molecular Testing) + (Cost of Radiology) + (Cost of Hospital
Treatment * Number of Days in the Hospital) + (Probability of ICU stay given a Correct LD
Diagnosis*Avg ICU Length of Stay * Cost of ICU per Day) + (Probability of death given correct
LD Diagnosis*Cost of ICU Stay * Additional days due to Death)
Cost_TP = CDMT + CDRT + (CHT * LOS_LD) + (P(ICU|CLDD)* CICU * LOS_ICU) +
(P(D|CLDD)* CICU * LOS_Death)
Cost False Positive = (Cost of Molecular Testing) + (Cost of Radiology) + (Cost of Hospital
Treatment * Number of Days in the Hospital) + (Probability of ICU stay given an incorrect LD
Diagnosis*Avg ICU Length of Stay * Cost of ICU per Day) + (Probability of death given
incorrect LD Diagnosis*Cost of ICU Stay * Additional days due to Death)
Cost_FP = CDMT + CDRT + (CHT * LOS_OP) + (ALOS_ICD * CHT) + ((P(ICU|CPD)+
AP(ICU|ICD))* CICU * LOS_ICU) + (P(D|ICLDD)* LOS_Death * CICU)
Cost False Negative = (Cost of Molecular Testing) + (Cost of Radiology) + (Cost of Hospital
Treatment * Number of Days in the Hospital) + (Probability of ICU stay given an incorrect
nonLD Diagnosis*Avg ICU Length of Stay * Cost of ICU per Day) + (Probability of death given
incorrect nonLD Diagnosis*Cost of ICU Stay * Additional days due to Death)
Cost_FN = CDMT + CDRT + (CHT * LOS_LD) + (ALOS_ICD * CHT) +
(P(ICU|CLDD)+AP(ICU|ICD))* LOS_ICU * CICU) + (P(D|ICPD)* LOS_Death * CICU)
Cost True Negative = (Cost of Molecular Testing) + (Cost of Radiology) + (Cost of Hospital
Treatment * Number of Days in the Hospital) + (Probability of ICU stay given a correct nonLD
Diagnosis*Avg ICU Length of Stay * Cost of ICU per Day) + (Probability of death given
incorrect nonLD Diagnosis*Cost of ICU Stay * Additional days due to Death)
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Cost_TN = CDMT + CDRT + (CHT * LOS_OP) + (P(ICU|CPD)* CICU * LOS_ICU) +
(P(D|CPD)* CICU * LOS_Death)
Cost TP
45,674
Cost FP
54,960
Cost FN
61,208
Cost TN
41,704
*These estimates roughly match averaged total costs within the database.
3. Decision analysis
A decision analysis was used to strike an evidence-based balance between the costs of overtesting and the clinical drawbacks from undertesting. This analysis took into account 1. the
proportion of hospitalized cases attributable to LD; 2. the cost ratio; 3. a measurement of the
accuracy of the test.
1
∗ 𝐶𝑜𝑠𝑡 𝑅𝑎𝑡𝑖𝑜 = 𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑅𝑎𝑡𝑖𝑜
𝑃𝑟𝑖𝑜𝑟 𝑂𝑑𝑑𝑠
𝑝(𝐷−) 𝐶𝑇𝑁 − 𝐶𝐹𝑃
𝑝(𝑋|𝐷+)
∗
=
𝑝(𝐷+) 𝐶𝑇𝑃 − 𝐶𝐹𝑁
𝑝(𝑋|𝐷−)
The cost ratio takes into account the different magnitudes of the cost of correct and incorrect
diagnoses. The likelihood ratio is a single number that quantifies how well the screen can
differentiate between cases and noncases. By comparing these values, the optimal cost
minimizing threshold was determined.
When considering an ROC curve, the likelihood ratio is also the point on the ROC curve that
optimizes the sensitivity and specificity of the test. Here, the likelihood ratio was calculated by
first calculating the combined sensitivity and specificity of the screen and testing strategy for
each threshold cut off.
Sensitivitycombined = Sensscreen * Senstest
Specificitycombined = Specscreen + (1-Specscreen)*(Spectest)
The sensitivity of the diagnostic test was set at 0.7, and the specificity at 0.99.20
The slope between these sensitivities and specificities was calculated and compared to the
product of 1/prior odds and the cost ratio to determine the threshold.
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4. ROC curves from the Screen

ROC curves were used
to examine the tradeoffs
between sensitivity and
specificity for each of
the models on their train
set, validation set, and
when possible out of
state data. ROC curves
were relatively uniform
and produced similar
AUC values.
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